Home | Molecular Cancer Therapeutics

Read the October 2017 Issue!
About the cover: From "Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma," by Ang, et al.
Editor's Pick: Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma
Joo Ern Ang, et al.
The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy
Michael P. Sanderson, et al.
JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer
Kazuhiko Shien, et al.
Modeling Therapy Resistance in BRCA1/2-Mutant Cancers
Amy Dréan, et al.

From the Current Issue

Small Molecule Therapeutics

Antitumor Effect of the Atypical Retinoid ST1926 in Acute Myeloid Leukemia and Nanoparticle Formulation Prolongs Lifespan and Reduces Tumor Burden of Xenograft Mice

Leeanna El-Houjeiri, Walid Saad, Berthe Hayar, Patrick Aouad, Nadim Tawil, Rana Abdel-Samad, Rita Hleihel, Maguy Hamie, Angelo Mancinelli, Claudio Pisano, Hiba El Hajj and Nadine Darwiche

Mol Cancer Ther October 1 2017 16 (10) 2047-2057; DOI:10.1158/1535-7163.MCT-16-0785
Large Molecule Therapeutics

Alpha Particle Enhanced Blood Brain/Tumor Barrier Permeabilization in Glioblastomas Using Integrin Alpha-v Beta-3–Targeted Liposomes

Anirudh Sattiraju, Xiaobing Xiong, Darpan N. Pandya, Thaddeus J. Wadas, Ang Xuan, Yao Sun, Youngkyoo Jung, Kiran Kumar Solingapuram Sai, Jay F. Dorsey, King C. Li and Akiva Mintz

Mol Cancer Ther October 1 2017 16 (10) 2191-2200; DOI:10.1158/1535-7163.MCT-16-0907
Cancer Biology and Signal Transduction

The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy

Michael P. Sanderson, Marco H. Hofmann, Pilar Garin-Chesa, Norbert Schweifer, Andreas Wernitznig, Stefan Fischer, Astrid Jeschko, Reiner Meyer, Jürgen Moll, Thomas Pecina, Heribert Arnhof, Ulrike Weyer-Czernilofsky, Stephan K. Zahn, Günther R. Adolf and Norbert Kraut

Mol Cancer Ther October 1 2017 16 (10) 2223-2233; DOI:10.1158/1535-7163.MCT-17-0336
Companion Diagnostics and Cancer Biomarkers | AuthorChoice

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

Joo Ern Ang, Akos Pal, Yasmin J. Asad, Alan T. Henley, Melanie Valenti, Gary Box, Alexis de haven Brandon, Victoria L. Revell, Debra J. Skene, Miro Venturi, Ruediger Rueger, Valerie Meresse, Suzanne A. Eccles, Johann S. de Bono, Stanley B. Kaye, Paul Workman, Udai Banerji and Florence I. Raynaud

Mol Cancer Ther October 1 2017 16 (10) 2315-2323; DOI:10.1158/1535-7163.MCT-16-0881

See the Table of Contents

Recent Reviews

Review

New B7 Family Checkpoints in Human Cancers

Ling Ni and Chen Dong

Mol Cancer Ther July 1 2017 16 (7) 1203-1211; DOI:10.1158/1535-7163.MCT-16-0761
Reviews

The Role of CtBP1 in Oncogenic Processes and Its Potential as a Therapeutic Target

Melanie A. Blevins, Mingxia Huang and Rui Zhao

Mol Cancer Ther June 1 2017 16 (6) 981-990; DOI:10.1158/1535-7163.MCT-16-0592
Reviews

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions

Maria Larrosa-Garcia and Maria R. Baer

Mol Cancer Ther June 1 2017 16 (6) 991-1001; DOI:10.1158/1535-7163.MCT-16-0876
Reviews

The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma

Antonio Ahn, Aniruddha Chatterjee and Michael R. Eccles

Mol Cancer Ther June 1 2017 16 (6) 1002-1009; DOI:10.1158/1535-7163.MCT-16-0535

Main menu

User menu

Search

From the Current Issue

Recent Reviews

OnlineFirst Articles

Articles

Info for

About MCT